Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2017 10/13/2017 10/16/2017 10/17/2017 10/18/2017 Date
37.76(c) 37.95(c) 38.18(c) 38.54(c) 37.51(c) Last
3 954 181 4 860 646 6 493 299 4 239 818 4 793 179 Volume
-1.38% +0.50% +0.61% +0.94% -2.67% Change
More quotes
Financials ($)
Sales 2017 12 073 M
EBIT 2017 3 324 M
Net income 2017 1 314 M
Debt 2017 13 503 M
Yield 2017 -
Sales 2018 12 676 M
EBIT 2018 3 737 M
Net income 2018 2 031 M
Debt 2018 11 287 M
Yield 2018 -
P/E ratio 2017 13,75
P/E ratio 2018 10,65
EV / Sales2017 2,78x
EV / Sales2018 2,48x
Capitalization 20 116 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom. 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/17 MYLAN : to Report Third Quarter 2017 Financial Results on Nov. 6, 2017
10/17 MYLAN : Invalidates Allergan's Patents on Restasis®
10/05 MYLAN : in Partnership with Synthon, Receives Marketing Authorization Approval i..
10/05 MYLAN NV : Mylan, Approval of Copaxone Should Provide an Accretive Boost, Generi..
10/05 MYLAN : Launches First AP-rated Generic Avelox® Injection
10/05 MYLAN : Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-W..
10/04 MYLAN : Provides Support for U.S. Disaster-Relief Efforts
10/04 MYLAN : Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Ti..
10/02 MYLAN : Launches Generic Cancidas® for Injection
More news
Sector news : Pharmaceuticals - NEC
02:19pDJEuropean Corporate Roundup for Thursday
11:31aDJEuropean Corporate Roundup for Thursday
08:48aDJMERCK AND : Chenault Among Few Black CEOs -- WSJ
07:53aDJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/18Ardsley Advisory Partners Takes Position in Mylan N.V. $MYL  
10/17"I don't think that happened," PBM group chief says of $MYL raising EpiPen pr.. 
10/17Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017  
10/17$MYL Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017 Fro.. 
10/17BRIEF-?Mylan invalidates Allergan's patents on Restasis?  
More tweets
Qtime:170
News from SeekingAlpha
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 ADAMIS PHARMACEUTICALS : Buy The Dip Ahead Of Symjepi Partnership And Launch
10/17 Allergan Punished After Judge Invalidates Restasis Patents
10/16 U.S. court invalidates Allergan's Restasis patents; shares down 5%
10/16 Mylan Calls Allergan's Mohawk Deal A 'Sham'
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 42,0 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-1.68%20 116
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214